Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on February 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on January 24th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 2/3/2025.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 1/31/2025.
• Purchased $50,001 – $100,000 in shares of Hawaiian Electric Industries (NYSE:HE) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of Agios Pharmaceuticals (NASDAQ:AGIO) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of SpringWorks Therapeutics (NASDAQ:SWTX) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Paragon 28 (NYSE:FNA) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of U.S. Physical Therapy (NYSE:USPH) on 1/29/2025.
• Purchased $1,001 – $15,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 1/29/2025.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $1.71 during midday trading on Thursday, hitting $156.97. The company’s stock had a trading volume of 2,685,083 shares, compared to its average volume of 8,838,490. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The stock has a fifty day moving average price of $147.58 and a 200 day moving average price of $156.00. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $377.91 billion, a price-to-earnings ratio of 23.59, a P/E/G ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the business posted $2.29 earnings per share. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.16%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Analyst Ratings Changes

A number of brokerages recently issued reports on JNJ. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Raymond James dropped their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Guggenheim increased their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Finally, Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Johnson & Johnson by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after buying an additional 1,772,706 shares in the last quarter. State Street Corp grew its position in shares of Johnson & Johnson by 0.9% in the third quarter. State Street Corp now owns 134,245,811 shares of the company’s stock valued at $21,755,874,000 after purchasing an additional 1,154,088 shares during the period. Geode Capital Management LLC grew its stake in shares of Johnson & Johnson by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock valued at $8,321,881,000 after buying an additional 1,561,036 shares during the period. Norges Bank acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $4,390,037,000. Finally, Wellington Management Group LLP raised its stake in shares of Johnson & Johnson by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock valued at $3,522,447,000 after purchasing an additional 431,205 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.